Previous 10 | Next 10 |
2023-10-08 08:15:00 ET For income-seeking investors, the only thing better than a solid dividend stock is a beaten-down one whose shares can be bought on the dip. And while the market has largely recovered this year, some dividend-paying corporations missed the memo and have substantially l...
2023-10-04 12:38:18 ET More on Novo Nordisk Novo Nordisk: DCF Analysis Suggests Significant Undervaluation Novo Nordisk: Catching The Falling Knife Now Could Really Hurt Novo Nordisk: What The Stock Split Means For Traders And Investors Novo Nordisk gains aft...
2023-10-04 12:24:03 ET More on Novo Nordisk Novo Nordisk: DCF Analysis Suggests Significant Undervaluation Novo Nordisk: Catching The Falling Knife Now Could Really Hurt Novo Nordisk: What The Stock Split Means For Traders And Investors Novo Nordisk gains aft...
2023-10-02 08:57:00 ET U.S. stock index futures on Monday were largely lower , as Wall Street kicked off a new month and the final quarter of 2023. The benchmark S&P 500 ( SP500 ) on Friday slumped to a nearly 5% loss for September, marking its worst monthly performance since De...
2023-10-02 06:35:13 ET More on Viatris Viatris: Generic Semaglutide Could Become The Poor Man's Option For Weight Loss Why 5%-Yielding Viatris Hasn't Doubled Yet Viatris Emerges As Challenger In Lucrative Anti-Obesity Drugs Market Novo Nordisk underperforms a...
Viatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDA PR Newswire Total Gross Proceeds From All Divestitures, Including the 2022 Divestiture of the Compan...
2023-10-01 12:00:03 ET More on Novo Nordisk Viatris: Generic Semaglutide Could Become The Poor Man's Option For Weight Loss Novo Nordisk: DCF Analysis Suggests Significant Undervaluation Novo Nordisk: Catching The Falling Knife Now Could Really Hurt Viatris a...
2023-09-30 07:58:00 ET If you're investing $25,000 in your stock portfolio, then getting that investment to be worth $1 million over time is no simple task. Odds are, you'll have to wait decades for that investment to grow 40 times its original value, while also likely outperforming the mar...
2023-09-29 15:00:25 ET Summary Viatris Inc.'s Q2 2023 earnings presentation notes that generic forms of NVO's Ozempic and Wegovy are under regulatory review. Despite newer therapies, older drugs like Trulicity continue to generate significant revenues, so a generic semaglutide cou...
2023-09-27 09:22:17 ET More on Ocuphire Pharma, Viatris, etc. Why 5%-Yielding Viatris Hasn't Doubled Yet Viatris Emerges As Challenger In Lucrative Anti-Obesity Drugs Market Viatris: Turning Point For Cheap Pharma Stock Viatris in talks to sell European OTC a...
News, Short Squeeze, Breakout and More Instantly...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / No country can make every medicine people need, and no medicine is made in every country. If a country or region relies on supply only from within their region and they experience a crisis, there is a risk people won't get the medicines they need, w...
NORTHAMPTON, MA / ACCESSWIRE / July 18, 2024 / Viatris is a global healthcare company focused on bringing high-quality medicines to patients through a hybrid approach that bridges the traditional divide between generics and brands, combining the best of both, to more holistically address healthc...
2024-07-15 10:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...